Yizhen Dong

Koch Disruptive Technologies (KDT) focuses on partnering with high-growth companies that disrupt current market alternatives with demonstrated technology. KDT looks for opportunities to create mutual benefit by working with principled entrepreneurs who can receive significant value from interacting with Koch companies and whose technology has the potential to transform Koch's core capabilities, create new capabilities, or expand Koch into new platforms.

Cellares is the first Integrated Development and Manufacturing Organization (IDMO) and takes an Industry 4.0 approach to mass manufacturing the living drugs of the 21st century. The company is both developing and operating integrated technologies for cell therapy manufacturing to accelerate access to life-saving cell therapies. The company’s Cell Shuttle integrates all the technologies required for the entire manufacturing process in a flexible and high-throughput platform that delivers true walk-away, end-to-end automation. Cell Shuttles will be deployed in Cellares’ Smart Factories around the world to meet total patient demand for cell therapies at global scale. Partnering with Cellares enables academics, biotechs, and pharma companies to accelerate drug development and scale out manufacturing, lower process failure rates, lower manufacturing costs, and meet global patient demand. The company is headquartered in South San Francisco, California with its commercial-scale IDMO Smart Factory in Bridgewater, New Jersey. The company is backed by world-class investors and has raised over $355 million in financing.

Our AI can prognosticate patient outcomes & personalize treatment in localized prostate cancer. Five Phase III randomized trials were used to develop prognostic and predictive AI biomarkers.

Synthace is a digital experiment platform built for high-performance life science R&D teams to help them run more powerful experiments and accelerate scientific progress. It allows biologists to design, plan, and automate experiments in a single place, then automatically gather structured experiment data and metadata in a unified no-code environment.

Hinge Health is focused on scaling and automating the delivery of health care, starting with musculoskeletal conditions. Leveraging an AI-powered care model, a wearable device, and access to expert clinicians, Hinge Health delivers personalized, evidence-based care that helps people move beyond pain, improving member outcomes and experiences and reducing costs for clients. The company is headquartered in San Francisco, California. We’re hiring! Join us at hingehealth.com/careers

Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies. The future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. At Deep Genomics, our geneticists, molecular biologists and chemists develop new ways of detecting and treating disease using our biologically accurate artificial intelligence technology.

DCVC and its principals have backed brilliant people changing global-scale industries for over twenty years, helping create tens of billions of dollars of wealth for founders, employees, and our investors while also making the world a markedly better place. DCVC brings to bear a unique model that unites a team of experienced venture capitalists with more than 35 technology executives and experts (CTOs, CIOs, Chief Scientists, Principal Engineers, Professors at Stanford and Berkeley) with significant tenures at top 100 technology companies and research institutions worldwide. DCVC focuses on seed, Series A, and growth stage companies that apply deep compute, big data and IT infrastructure technologies to transform giant industries. Learn more about us at www.dcvc.com, read our thinking at https://medium.com/@dcvc, and follow us on twitter at @dcvc.

HPA is a leading early-stage investor. Our People First model leverages world-class operating expertise, a powerful business network, and venture capital to fuel startup success. As a result, our founders transform their businesses into industry leaders, our investors generate best-in-class returns, and our community experiences job creation and economic growth.

Koch Disruptive Technologies (KDT) focuses on partnering with high-growth companies that disrupt current market alternatives with demonstrated technology. KDT looks for opportunities to create mutual benefit by working with principled entrepreneurs who can receive significant value from interacting with Koch companies and whose technology has the potential to transform Koch's core capabilities, create new capabilities, or expand Koch into new platforms.

Cellares is the first Integrated Development and Manufacturing Organization (IDMO) and takes an Industry 4.0 approach to mass manufacturing the living drugs of the 21st century. The company is both developing and operating integrated technologies for cell therapy manufacturing to accelerate access to life-saving cell therapies. The company’s Cell Shuttle integrates all the technologies required for the entire manufacturing process in a flexible and high-throughput platform that delivers true walk-away, end-to-end automation. Cell Shuttles will be deployed in Cellares’ Smart Factories around the world to meet total patient demand for cell therapies at global scale. Partnering with Cellares enables academics, biotechs, and pharma companies to accelerate drug development and scale out manufacturing, lower process failure rates, lower manufacturing costs, and meet global patient demand. The company is headquartered in South San Francisco, California with its commercial-scale IDMO Smart Factory in Bridgewater, New Jersey. The company is backed by world-class investors and has raised over $355 million in financing.

Our AI can prognosticate patient outcomes & personalize treatment in localized prostate cancer. Five Phase III randomized trials were used to develop prognostic and predictive AI biomarkers.

Global Founders Capital is a globally oriented, stage agnostic venture capital firm that empowers gifted entrepreneurs worldwide. 01 // Global. We support founders in all geographies. 02 // Stage agnostic. We back companies across all stages and throughout the lifecycle. 03 // Operational. Our platform offers founders all the support they need to scale. If you are interested in joining one of our portfolio companies, please join us on our Talent Pool: https://circular.io/r/kim.dang+vc

Synthace is a digital experiment platform built for high-performance life science R&D teams to help them run more powerful experiments and accelerate scientific progress. It allows biologists to design, plan, and automate experiments in a single place, then automatically gather structured experiment data and metadata in a unified no-code environment.